Background Continuous positive airway pressure (CPAP) for symptomatic obstructive sleep
apnoea (OSA) improves sleepiness and reduces vascular risk, but such treatment for the …

Background: Obstructive sleep apnoea (OSA) is associated with high cardiovascular
morbidity and mortality. Randomised controlled trials have shown that, on average …

Background A strong association between obstructive sleep apnea (OSA) and the risk for
cardiovascular and cerebrovascular diseases has been reported. Continuous positive …

Background Hypoxic burden (HB) has emerged as a strong predictor of cardiovascular risk
in obstructive sleep apnoea (OSA). We aimed to assess the potential of HB to predict the …

Background It remains uncertain whether continuous positive airway pressure (CPAP)
therapy would significantly impact hard clinical outcomes in patients with obstructive sleep …

Context Continuous positive airway pressure (CPAP) is the first-line treatment for patients
with symptomatic obstructive sleep apnea (OSA). However, its indication for all patients with …

Obstructive sleep apnoea (OSA) is associated with high cardiovascular morbidity and
mortality. Several randomised controlled trials have shown that continuous positive airway …

Aims To assess whether continuous positive airway pressure (CPAP) therapy reduces major
adverse cardiovascular events (MACE) in patients with moderate-to-severe obstructive …

Background: It is unclear whether continuous positive airway pressure (CPAP), the treatment
of choice for severe obstructive sleep apnoea (OSA), is effective at improving outcomes in …

Objective Most studies have used cardiovascular and cerebrovascular disease (CVD) end-
points to measure the effect of continuous positive airway pressure (CPAP), but pre …